Advancing America’s Interests Act

Issues related to Patents, International Trade Commission Issues related to ITC Section 337 Investigations in the Advancing American Interests Act (H.R. 3535) Issues related to scope and applicability of provisions in the Patent Eligibility Restoration Act (S. 2140) Issues related to scope and applicability of provisions in the The Promoting and Respecting Economically Vital American Innovation Leadership Act (S. 2220)

Client expense: $190,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023 S. 4713 - The IDEA Act (Inventor Diversity for Economic Advancement Act) S. 4840/ H.R. 9221 - Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act) Ensure free-market-based licensing terms and royalty rate settings of standard-essential patents (SEPs) Codification of 2019 Joint Policy Statement on Remedies for Standards-Essential Patents

Client expense: Not reported · Firm income: $7,600

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General patent policy, including issues related to the Patent Trial and Appeal Board and S. 2220, the PREVAIL Act Issues related to standard essential patents Issues related to anti-counterfeit policy General trademark and copyright policy Issues related to patent proceedings and the International Trade Commission, including H.R. 3535, the Advancing Americas Interests Act General overview of music licensing legal framework

Client expense: $1,900,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 . S. 1250 Drug-price Transparency for Consumers Act S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting S.2140 Patent Eligibility Restoration Act of 2023 S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress. H.R. 3535 Advancing Americas Interests Act H.R. 5475 Prohibiting Adversarial Patents Act of 2023 S.3385/HR 8333-- BIOSECURE Act BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities Issues related to FDA/PTO coordination S.2780 Medication Affordability and Patent Integrity Act Issues related to skinny labeling S. 3583/HR 6986 To Address Patent Thickets S. 1956 Invent It Here, Make It Here Act

Client expense: $2,770,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3535, Advancing America's Interests Act Issues related to US patent policies

Client expense: $1,600,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

Issues relating to patent litigation and processes, protecting and modernizing intellectual property rights, and USPTO policies and operations: H.R. 4370/S.2220, "PREVAIL" Act (Senate and House); S.2140, Patent Eligibility Restoration Act of 2023; H.R. 3535, Advancing Americas Interests Act.

Client expense: $1,580,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

IP enforcement at the International Trade Commission; H.R. 3535, Advancing America's Interests Act; Annual appropriations related to reforms on the way the International Trade Commission handles patent cases and encouraging transparency in third party litigation funding

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. International Trade Commission (ITC)

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023 S. 4713 - The IDEA Act (Inventor Diversity for Economic Advancement Act) S. 4840/ H.R. 9221 - Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3535 - Advancing America's Interests Act; Issues regarding Section 337.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Patents, International Trade Commission Issues related to Right to Repair, Intellectual Property, Consumer Protection, cyber security and trade secrets for consumer electronics in the Fair Repair Act (H.R. 8544 & S. 4422) Issues related to ITC Section 337 Investigations in the Advancing American Interests Act (H.R. 3535) Issues related to scope and applicability of provisions in the Patent Eligibility Restoration Act (S. 2140) Issues related to scope and applicability of provisions in the The Promoting and Respecting Economically Vital American Innovation Leadership Act (S. 2220)

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent reform, Patent Trial and Appeal Board reform, assertion of patent exclusivity rights, H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840/H.R. 9221 (RESTORE Patent Rights Act), S. 2140/H.R. 9474 (Patent Eligibility Restoration Act), S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership Act), H.R. 3535 (Advancing Americas Interest Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

H.R. 3535 (Advancing Americas Interest Act), Bayh-Dole march-in, S. 2220/H.R. 4370 (PREVAIL Act), S. 2140 (Patent Eligibility Restoration Act), H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840 (RESTORE Patent Rights Act) H.R. 1 (Lower Energy Costs Act), H.R. 1640(Save Our Gas Stoves Act) Gov't. price controls Consumer welfare standard, DOJ Antitrust Div., Federal Trade Commission H.J. Res. 27/S.J. Res. 7 (Cong'l. disapproval EPA WOTUS rule) S. 1108/H.R. 7035 (Death Tax Repeal Act) H.R. 3746 (Fiscal Responsibility Act) H.R. 6758 (Defense of Property Rights Act) H.R. 7455 (Sunset Act)

Client expense: Not reported · Firm income: Not reported

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act)

Client expense: Not reported · Firm income: $53,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act)

Client expense: Not reported · Firm income: $53,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

General patent policy, including issues related to the Patent Trial and Appeal Board Issues related to standard essential patents Issues related to anti-counterfeit policy General trademark and copyright policy Issues related to patent proceedings and the International Trade Commission, including H.R. 3535, the Advancing Americas Interests Act General overview of music licensing legal framework

Client expense: $2,130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to patent litigation and processes, protecting and modernizing intellectual property rights, and USPTO policies and operations: H.R. 4370/S.2220, "PREVAIL" Act (Senate and House); S.2140, Patent Eligibility Restoration Act of 2023; H.R. 3535, Advancing Americas Interests Act.

Client expense: $1,580,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 . S. 1250-the Drug-price Transparency for Consumers Act S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting S.2140 Patent Eligibility Restoration Act of 2023 S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress. H.R. 3535 Advancing Americas Interests Act H.R. 5475 Prohibiting Adversarial Patents Act of 2023 S.3385/HR 8333-- BIOSECURE Act BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities

Client expense: $2,740,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - PREVAIL Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

IP enforcement at the International Trade Commission; H.R. 3535, Advancing America's Interests Act; Annual appropriations related to reforms on the way the International Trade Commission handles patent cases and encouraging transparency in third party litigation funding

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. International Trade Commission (ITC)

Advancing America's Interests Act (HR 3535) Issues related to US patent policies

Client expense: $2,010,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

H.R. 3535 - Advancing America's Interests Act; Issues regarding Section 337.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Patents, International Trade Commission Issues related to Right to Repair, Intellectual Property, Consumer Protection, cyber security and trade secrets for consumer electronics Issues related to ITC Section 337 Investigations in the Advancing American Interests Act (H.R. 3535)

Client expense: $160,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

CPT: Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act)

Client expense: Not reported · Firm income: $19,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

Antitrust Legislation Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights ---Reasonable Pricing Clause ---NIST RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March in Rights Compulsory Licensing ---28 USC 1498 Government Use of Patents ---Prescription Drug Price Relief Act (Discussion Draft) Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights ---TRIPS Waiver Data Privacy Issues ---H.R.7085: BIOSECURE Act -------At the direction of its core members, BIO advocated on behalf of the biotech industry to avoid supply chain disruptions that would interrupt treatments and cures for patients. During February 2024, BIO coordinated some of this advocacy with WuXiAppTec (then an associate member of BIO) and with other BIO members also, seeking removal of the list of entities specifically named in the proposed legislation being referenced as the BIOSECURE Act, which included WuXiAppTec. ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---American Data Privacy and Protection Act ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---Ranking Member Cassidy RFI on Improving Americans Health Data Privacy Diversity in Patenting ---S.2566: Inventor Diversity for Economic Advancement (IDEA) Act Drug Patenting ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents ---S.3583/H.R.6986: A bill to address patent thickets ---CLEAR Patents Act ---Interagency Patent Coordination and Improvement Act ---Restrictions on Intellectual Property Rights Foreign Drug Data Protection Law ---H.R.7085: BIOSECURE Act -------At the direction of its core members, BIO advocated on behalf of the biotech industry to avoid supply chain disruptions that would interrupt treatments and cures for patients. During February 2024, BIO coordinated some of this advocacy with WuXiAppTec (then an associate member of BIO) and with other BIO members also, seeking removal of the list of entities specifically named in the proposed legislation being referenced as the BIOSECURE Act, which included WuXiAppTec. ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Intellectual Property Enforcement ---TRIPS Waiver Patent Reform ---H.R.3535: Advancing Americas Interest Act ---H.R.4575: Prohibiting Adversarial Patents Act (PAPA) ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.2140: Patent Eligibility Restoration Act (PERA) ---S.2220/H.R.4370: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act ---S.4417: Patent Trial and Appeal Board Reform Act of 2022 ---Patent Litigation Reform Patenting of Biological Inventions ---S.2140: Patent Eligibility Restoration Act (PERA) ---Section 101 Modernization ---PTO Examination Guidelines United States-Mexico-Canada Agreement (USMCA) ---Implementation of USMCA World Health Organization (WHO) ---WHO Pandemic Preparedness Accord World Intellectual Property Office (WIPO) ---Intergovernmental Committee on IP and Genetic Resources World Trade Organization (WTO) ---13th Ministerial Conference ---TRIPS Waiver

Client expense: $1,760,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office

Antitrust Legislation Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights ---Reasonable Pricing Clause ---NIST RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March in Rights Compulsory Licensing ---28 USC 1498 Government Use of Patents ---Prescription Drug Price Relief Act (Discussion Draft) Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights ---TRIPS Waiver Data Privacy Issues ---H.R.7085: BIOSECURE Act -------At the direction of its core members, BIO advocated on behalf of the biotech industry to avoid supply chain disruptions that would interrupt treatments and cures for patients. During February 2024, BIO coordinated some of this advocacy with WuXiAppTec (then an associate member of BIO) and with other BIO members also, seeking removal of the list of entities specifically named in the proposed legislation being referenced as the BIOSECURE Act, which included WuXiAppTec. ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---American Data Privacy and Protection Act ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---Ranking Member Cassidy RFI on Improving Americans Health Data Privacy Diversity in Patenting ---S.2566: Inventor Diversity for Economic Advancement (IDEA) Act Drug Patenting ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents ---S.3583/H.R.6986: A bill to address patent thickets ---CLEAR Patents Act ---Interagency Patent Coordination and Improvement Act ---Restrictions on Intellectual Property Rights Foreign Drug Data Protection Law ---H.R.7085: BIOSECURE Act -------At the direction of its core members, BIO advocated on behalf of the biotech industry to avoid supply chain disruptions that would interrupt treatments and cures for patients. During February 2024, BIO coordinated some of this advocacy with WuXiAppTec (then an associate member of BIO) and with other BIO members also, seeking removal of the list of entities specifically named in the proposed legislation being referenced as the BIOSECURE Act, which included WuXiAppTec. ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Intellectual Property Enforcement ---TRIPS Waiver Patent Reform ---H.R.3535: Advancing Americas Interest Act ---H.R.4575: Prohibiting Adversarial Patents Act (PAPA) ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.2140: Patent Eligibility Restoration Act (PERA) ---S.2220/H.R.4370: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act ---S.4417: Patent Trial and Appeal Board Reform Act of 2022 ---Patent Litigation Reform Patenting of Biological Inventions ---S.2140: Patent Eligibility Restoration Act (PERA) ---Section 101 Modernization ---PTO Examination Guidelines United States-Mexico-Canada Agreement (USMCA) ---Implementation of USMCA World Health Organization (WHO) ---WHO Pandemic Preparedness Accord World Intellectual Property Office (WIPO) ---Intergovernmental Committee on IP and Genetic Resources World Trade Organization (WTO) ---13th Ministerial Conference ---TRIPS Waiver

Client expense: $1,760,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office

General patent policy, including issues related to the Patent Trial and Appeal Board Issues related to standard essential patents Issues related to anti-counterfeit policy General trademark and copyright policy Issues related to patent proceedings and the International Trade Commission, including H.R. 3535, the Advancing Americas Interests Act General overview of music licensing legal framework

Client expense: $2,130,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - PREVAIL Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

IP enforcement at the International Trade Commission; H.R. 3535, Advancing America's Interests Act; Annual appropriations related to reforms on the way the International Trade Commission handles patent cases and encouraging transparency in third party litigation funding

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. International Trade Commission (ITC)

Issues relating to patent litigation and processes, protecting and modernizing intellectual property rights, and USPTO policies and operations: H.R. 4370/S.2220, "PREVAIL" Act (Senate and House); S.2140, Patent Eligibility Restoration Act of 2023; H.R. 3535, Advancing Americas Interests Act.

Client expense: $1,690,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advancing America's Interests Act (HR 3535) Issues related to US patent policies

Client expense: $1,610,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

Issues related to Patents, International Trade Commission Issues related to ITC Section 337 Investigations in the Advancing American Interests Act (H.R. 3535) Issues related to Right to Repair, Intellectual Property, Consumer Protection, cyber security and trade secrets for consumer electronics

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3535 - Advancing America's Interests Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES

S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to False Claims Act Issues related to FDA/PTO coordination Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting S.2140 Patent Eligibility Restoration Act of 2023 S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress. H.R. 3535 Advancing Americas Interests Act H.R. 5475 Prohibiting Adversarial Patents Act of 2023

Client expense: $3,330,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill S.2140 Patent Eligibility Restoration Act of 2023 S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress. H.R. 3535 Advancing Americas Interests Act H.R. 5475 Prohibiting Adversarial Patents Act of 2023 Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to False Claims Act Issues related to FDA/PTO coordination Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting

Client expense: $2,980,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 621/ S. 154: Preventing Auto Recycling Thefts (PART) Act HR 906: REPAIR Act HR 1435: Preserving Choice in Vehicle Purchases Act HR 1707: SMART Act HR 2948: Carrying Automobiles Responsibly and Safely (CARS) Act HR 3337: Fuels Parity Act HR 3413/ S 1669: AM Radio for Every Vehicle Act HR 3535: Advancing Americas Interests Act HR 4468: Choice in Automobile Retail Sales Act of 2023 (CARS Act) HR 4469: No Fuel Credits for Batteries Act of 2023 S 2061: Catalytic Converter Theft Task Force Act Artificial Intelligence Issues CAFE Civil Penalties Critical Minerals Legislation DOT New Vehicle Fuel Economy Standards for Model Year 2027-2031 Draft Autonomous Vehicle Legislation Draft Consumer Awareness Legislation Draft E-RINS Legislation Draft Electric Vehicle Infrastructure Legislation Draft Electric Vehicle Incentive Legislation Draft Privacy Legislation Draft Right to Repair Legislation Draft SEP legislation Environmental, social and governance (ESG) and diversity, equity and inclusion (DEI) matters EPA-HQ-OAR-2022-0829 Proposed Rule: Multi-Pollutant Emissions Standards for Model Years 2027 and Later Light-Duty and Medium-Duty Vehicles FY 2023 National Defense Authorization Act GHG/CAFE National Electric Vehicle Infrastructure Program (IIJA) National Highway Traffic Safety Administration Corporate Average Fuel Economy (CAFE) standards Petroleum Equivalency Factor (PEF) and Electric Vehicles Pub. L. 117-167: CHIPS and Science Act Implementation Pub. L. 117-169: Implementation of the Inflation Reduction Act Semiconductor Supply Chain Shifting Forward Vehicle Technologies Research and Development Act Surface Transportation Board matters Telematics

Client expense: $1,382,319 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, White House Office

HR 621/ S. 154: Preventing Auto Recycling Thefts (PART) Act HR 906: REPAIR Act HR 1435: Preserving Choice in Vehicle Purchases Act HR 1707: SMART Act HR 3337: Fuels Parity Act HR 3413/ S 1669: AM Radio for Every Vehicle Act HR 3535: Advancing Americas Interests Act Artificial Intelligence Issues CAFE Civil Penalties Critical Minerals Legislation DOT New Vehicle Fuel Economy Standards for Model Year 2027-2031 Draft Autonomous Vehicle Legislation Draft Choice in Automobile Retail Sales (CARS) Act Draft Consumer Awareness Legislation Draft Counterfeit Parts Legislation Draft Data Legislation Draft E-RINS Legislation Draft Electric Vehicle Infrastructure Legislation Draft Electric Vehicle Incentive Legislation Draft legislation affecting the truck transport of electric vehicles (Stinger weight coalition) Draft Privacy Legislation Draft Right to Repair Legislation Draft SEP legislation Draft SHOP SAFE Legislation EPA-HQ-OAR-2022-0829 Proposed Rule: Multi-Pollutant Emissions Standards for Model Years 2027 and Later Light-Duty and Medium-Duty Vehicles Federal Motor Vehicle Safety Standard (FMVSS) No. 209 GHG/CAFE National Electric Vehicle Infrastructure Program (IIJA) Promoting Auto Recalls Toward Safety (PARTS) Act Pub. L. 117-169: Implementation of the Inflation Reduction Act Semiconductor Supply Chain Stay Aware for Everyone (SAFE) Act Surface Transportation Board matters Telematics

Client expense: $1,421,433 · Firm income: Not reported

Government targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Highway Traffic Safety Administration (NHTSA), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, White House Office